In line with growing concerns that certain Covid-19 vaccines are causing unusual blood clotting problems, a group of scientists from the U.K. conducted a massive study on the link between vaccinations and dropping platelet counts and found that the problem lies more on the virus itself than on the medications.
A group of scientists from the Nuffield Department of Women’s & Reproductive Health at Oxford University may have found a potential key to finally treating endometriosis, a disease that affects around 176 million women worldwide.
A British public health study found that protection from either of the two most commonly used Covid-19 vaccines against the prevalent Delta variant of the coronavirus weakens within three months.
Second-quarter 2021 sales of AstraZeneca’s Covid-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on July 29 again delayed the U.S. application for approval as the company gathers more data for submissions.
AstraZeneca’s Covid-19 vaccine carries a small extra risk of rare blood clots with low platelets after the first dose and no extra risk after the second, a study led and funded by the drugmaker showed on July 28, after worries over side effects.
Scientists are working on a benchmark for Covid-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
University of Oxford researchers started clinical trials for a new vaccine that can potentially target a wide range of human immunodeficiency virus (HIV) variants.
A mixed schedule of vaccines where a shot of Pfizer’s Covid-19 vaccine is given four weeks after an AstraZeneca shot will produce better immune responses than giving another dose of AstraZeneca, an Oxford study said on June 28.
A third shot of the Oxford-AstraZeneca Covid-19 vaccine produces a strong immune response, researchers said on June 28, adding there was not yet evidence that such shots were needed, especially given shortages in some countries.
AstraZeneca, Pfizer vaccines effective against Delta Covid-19 variants – study
AstraZeneca, BioNTech, BNT162b2 (Pfizer and BioNTech), COVID-19 Studies, COVID-19 Vaccines, Covid-19 Variants, Delta Variant (B.1.617.2; India), India, Oxford University, Pfizer, Public Health England (PHE), World Health OrganizationCovid-19 vaccines made by AstraZeneca and the Pfizer-BioNTech alliance remain broadly effective against Delta and Kappa variants of the Covid-19 causing virus that were first identified in India, according to a scientific study, underpinning a continued push to deliver the shots.